You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Litigation Details for Allergan Inc. v. Barr Laboratories Inc. (D. Del. 2009)

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Allergan Inc. v. Barr Laboratories Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-05-07
Court District Court, D. Delaware Date Terminated 2011-09-22
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Both Referred To Judge Mary Pat Thynge
Patents 4,599,353; 5,510,383; 5,688,819; 6,403,649
Attorneys Ali Ahmed; Bradley C. Graveline; Brandon C. Helms; Brian E. Farnan; Douglas Edward McCann; Eric L. Broxterman; George C. Lombardi; Gina J. Oka; Jennifer Lynne Hall; John C. Phillips , Jr.; Jonathan E. Singer; Kevin E. Warner; Lindsay M. Beyer; Megan C. Haney; Michael K. Nutter; Ryanne Easley; Trang Hoang; William J. Marsden , Jr.
Link to Docket External link to docket
Small Molecule Drugs cited in Allergan Inc. v. Barr Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Allergan Inc. v. Barr Laboratories Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-05-07 1 Complaint 4,183,870 1/1980 Caton et al. . 4,599,353 7/1986 Bito . … compounds, which may be substi- 4,599,353 A 7/1986 Bito …cyelopentane In the U. S. Pat. No. 4,599,353 certain Prostaglandins, in heptanoic acid…infringement of United States Patent Nos. 5,688,819 (the "'819 patent") and 6,403,649 (the …and interest in the '819 patent. 10. The '649 patent, entitled "Non-Acidic Cyclopentane External link to document
2011-04-01 217 POST Trial Brief U.S. Patent No. 5,688,819 (“the ’819 patent”) and the invalidity of Claims 1-3 of U.S. Patent No. 6,403,649…work, but because Pharmacia’s Bito patent provided “a powerful patent position” covering PGF2α prodrugs…compounds taught by the Stjernschantz patent, the patents-in-suit are inherently anticipated. Claims…compounds. Great Britain Patent Specification No. 1324737 (“GB ’737”) and Canadian Patent No. 986926 (“CA … § 103 likely bars its patentability.”). Claim 1 of the ’649 patent—i.e., bimatoprost—is thus External link to document
2011-09-08 236 Opinion references: Stjernschantz, U.S. Patent No. 4,599,353 (“the Bito patent”) (DTX-450); JP ‘636 (DTX-994)…Orange Book patents at issue in this case: U.S. Patent No. 5,688,819 ("the '819 patent") …U.S. Patent No. 5,352,708 (“the ‘708 patent”). (D.I. 210 at 159:5-161:20) The ‘708 patent does…specification of the ‘708 patent as well as the other patents in the chain. (‘819 patent, col. 1:7-15) The…incorporates the ‘708 patent by reference. (‘619 patent, col. 1:7-18) 10. The patents-in-suit disclose External link to document
2011-09-22 240 Judgment .S. Patent 5,688,819 (“the ’819 patent”) and claims 1-3 of U.S. Patent 6,403,649 (“the ’649 patent”) (…asserted claims of the patents-in-suit. 4. The asserted claims of the patents-in-suit are not invalid… (hereinafter “the asserted claims of the patents-in-suit”). 2. Barr, Teva USA and Teva Ltd.’s proposed…ication 91-194 infringe the asserted claims of the patents-in-suit. 3. Sandoz’s proposed products described…latest of the expiration dates of the ’819 and ’649 patents 6. Pursuant to 35 U.S.C. § 271(e)(4)(A), the effective External link to document
2011-09-22 241 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,688,819; 6,403,649 B1. (nmf…22 September 2011 1:09-cv-00333-SLR-MPT Patent Both District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.